Abstract
Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
